Valeska Balderas, MD
Gastroenterology · McAllen, TXNPI 1588866370
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,357 of the $6,695 with a category attached, or 65.1%. 18 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 38.0% of the total. Reporting peaked in 2019 at $2,725 and has fallen 66.5% since, to $914 in 2025.
Across 299 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$968
- Ardelyx, Inc.$272
- Gilead$177
- Johnson & Johnson$169
- plus $831 from 12 others
Across 2 payments — averaging $5032.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Adare Pharmaceuticals, Inc.$10K
What the payments were for
- Speaking & faculty fees$2,28334%
- Food & beverage$4,35765%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $2,546 |
| AbbVie(2 entities) | 90 | $1,730 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 118 | $968 |
| Ardelyx, Inc. | 12 | $272 |
| Gilead | 8 | $177 |
| Johnson & Johnson | 3 | $169 |
| Bristol Myers Squibb | 10 | $169 |
| Boston Scientific | 4 | $165 |
| Madrigal Pharmaceuticals | 2 | $125 |
| Pfizer | 3 | $76 |
| Nestle Healthcare Nutrition Inc. | 4 | $64 |
| Intercept Pharmaceuticals, Inc. | 5 | $63 |
| Aimmune Therapeutics, Inc. | 3 | $43 |
| Lilly USA, LLC | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Ipsen Biopharmaceuticals, Inc | 2 | $29 |
| Sanofi | 1 | $23 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,695 in reported general payments places this provider in the 70th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 27 | $695,873 |
| XifaxanRifaximin | 88 | $277,656 |
| LinzessLinaclotide | 236 | $234,397 |
| ZenpepLipase/Protease/Amylase | 49 | $159,373 |
| CreonLipase/Protease/Amylase | 51 | $151,318 |
| Humira(Cf) PenAdalimumab | 14 | $97,412 |
| Humira PenAdalimumab | 14 | $90,240 |
| TrulancePlecanatide | 87 | $75,783 |
| RezdiffraResmetirom | 11 | $60,037 |
| Famotidine | 791 | $15,631 |
| Ursodiol | 115 | $15,538 |
| Sucralfate | 188 | $12,800 |
| Dexlansoprazole DrDexlansoprazole | 36 | $11,144 |
| Lactulose | 164 | $9,071 |
| Mesalamine ErMesalamine | 34 | $7,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $169 | $695,87327 claims |
| AbbVieLinzess, Creon | $1,730 | $385,715287 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $968 | $353,440175 claims |
| Aimmune Therapeutics, Inc.Zenpep | $43 | $159,37349 claims |
| Madrigal PharmaceuticalsRezdiffra | $125 | $60,03711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in McAllen
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Anish PatelFort Sam Houston$1.3M
- Timothy RitterSouthlake$961K
- Parvez MantryDallas$958K
- Nadege GunnWaco$933K
- Brooks CashHouston$867K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.